A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
← catalyst calendarNCT07332000 · readout ≤ 12 d
Sponsored by Candel Therapeutics, Inc. (industry) · CADL — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
45estimated
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-30 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Prostate Cancer Patients Treated by Radiotherapy
- Prostate Cancer (Adenocarcinoma)
Interventions
- Biological: aglatimagene besadenovec + valacyclovir — also filed as CAN-2409 plus prodrug
- Radiation: External Beam Radiation Therapy (EBRT)
Primary outcome
what the primary-completion date above is the date OFBiodistribution of aglatimagene besadenovec
measured Up to 3 months post last injection of aglatimagene besadenovec.
Permalink · CADL's whole pipeline · Catalyst calendar · Every registered study · What changed